Download fulltext
HTML
1.
Dalvin LA. Editorial – Thiolated Chitosan-carboxymethyl Dextran Nanoparticles: Improving Intravitreal Drug Bioavailability for Retinoblastoma. JOVR [Internet]. 2022Jan.21 [cited 2024Jul.17];17(1):1–3. Available from: https://knepublishing.com/index.php/JOVR/article/view/10163
https://doi.org/10.18502/jovr.v17i1.10163
statistics
- 702 Abstract Views
- 568 PDF Views
- 0 HTML Views
authors
-
Lauren A Dalvin
Lauren A Dalvin
Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA
Published Date
- Jan 21, 2022
Editorial – Thiolated Chitosan-carboxymethyl Dextran Nanoparticles: Improving Intravitreal Drug Bioavailability for Retinoblastoma
Abstract
This is an Editorial. Please download the PDF or view the article HTML.
Keywords:
Not applicable
References
1. Delrish E, Ghasemi F, Jabbarvand M, Lashay A, Atyabi F, Soleimani M, et al. Biodistribution of Cy5-labeled Thiolated and Methylated Chitosan-Carboxymethyl Dextran Nanoparticles in an Animal Model of Retinoblastoma. J Opthalmic Vis Res 2022;17:58–68.
2. Broaddus E, Topham A, Singh AD. Incidence of retinoblastoma in the USA: 1975–2004. Br J Ophthalmol 2009;93:21–23.
3. Stacey AW, Bowman R, Foster A, Kivelä TT, Munier FL, Cassoux N, et al. Incidence of retinoblastoma has increased: results from 40 European countries. Ophthalmology 2021;128:1369–1371.
4. Fabian ID, Abdallah E, Abdullahi SU, Abdulqader RA, Boubacar SA, Ademola-Popoola DS, et al. Global retinoblastoma presentation and analysis by national income level. JAMA Oncol 2020;6:685–695.
5. Dalvin LA, Kumari M, Essuman VA, Shipa SS, Ancona- Lezama D, Lucio-Alvarez JA, et al. Primary intra-arterial chemotherapy for retinoblastoma in the intravitreal chemotherapy era: five years of experience. Ocul Oncol Pathol 2019;5:139–146.
6. Agrahari V, Mandal A, Agrahari V, Trinh HM, Joseph M, Ray A, et al. A comprehensive insight on ocular pharmacokinetics. Drug Deliv Transl Res 2016;6:735–754.
7. Willekens K, Reyns G, Diricx M, Vanhove M, Noppen B, Coudyzer W, et al. Intravitreally injected fluid dispersion: importance of injection technique. Invest Ophthalmol Vis Sci 2017;58:1434–1441.
8. Bonfiglio A, Repetto R, Siggers JH, Stocchino A. Investigation of the motion of a viscous fluid in the vitreous cavity induced by eye rotations and implications for drug delivery. Phys Med Biol 2013;58:1969–1982.
9. Modareszadeh A, Abouali O, Ghaffarieh A, Ahmadi G. Saccade movements effect on the intravitreal drug delivery in vitreous substitutes: a numerical study. Biomech Model Mechanobiol 2013;12:281–290.
10. Buitrago E, Winter U, Williams G, Asprea M, Chantada G, Schaiquevich P. Pharmacokinetics of melphalan after intravitreal injection in a rabbit model. J Ocul Pharmacol Ther 2016;32:230–235.
11. Ilochonwu BC, Urtti A, Hennink WE, Vermonden T. Intravitreal hydrogels for sustained release of therapeutic proteins. J Control Release 2020;326:419–441.
12. Mohammed MA, Syeda JTM, Wasan KM, Wasan EK. An overview of chitosan nanoparticles and its application in non-parenteral drug delivery. Pharmaceutics 2017;9: 53.
13. Zamboulis A, Nanaki S, Michailidou G, Koumentakou I, Lazaridou M, Ainali NM, et al. Chitosan and its derivatives for ocular delivery formulations: recent advances and developments. Polymers 2020;12:1519.
14. Liu D, Li J, Pan H, He F, Liu Z, Wu Q, et al. Potential advantages of a novel chitosan-N-acetylcysteine surface modified nanostructured lipid carrier on the performance of ophthalmic delivery of curcumin. Sci Rep 2016;6: 28796.
15. Bernkop-Schnürch A, Hornof M, Guggi D. Thiolated chitosans. Eur J Pharm Biopharm 2004;57:9–17.
16. Gilbert RE, Cox AJ, Kelly DJ, Wilkinson-Berka JL, Sage EH, Jerums G, et al. Localization of secreted protein acidic and rich in cysteine (SPARC) expression in the rat eye. Connect Tissue Res 1999;40:295–303.
17. Koo H, Moon H, Han H, Na JH, Huh MS, Park JH, et al. The movement of self-assembled amphiphilic polymeric nanoparticles in the vitreous and retina after intravitreal injection. Biomaterials 2012;33:3485–3493.
18. Delrish E, Jabbarvand M, Ghassemi F, Amoli FA, Atyabi F, Lashay A, et al. Efficacy of topotecan nanoparticles for intravitreal chemotherapy of retinoblastoma. Exp Eye Res 2021;204:108423.
2. Broaddus E, Topham A, Singh AD. Incidence of retinoblastoma in the USA: 1975–2004. Br J Ophthalmol 2009;93:21–23.
3. Stacey AW, Bowman R, Foster A, Kivelä TT, Munier FL, Cassoux N, et al. Incidence of retinoblastoma has increased: results from 40 European countries. Ophthalmology 2021;128:1369–1371.
4. Fabian ID, Abdallah E, Abdullahi SU, Abdulqader RA, Boubacar SA, Ademola-Popoola DS, et al. Global retinoblastoma presentation and analysis by national income level. JAMA Oncol 2020;6:685–695.
5. Dalvin LA, Kumari M, Essuman VA, Shipa SS, Ancona- Lezama D, Lucio-Alvarez JA, et al. Primary intra-arterial chemotherapy for retinoblastoma in the intravitreal chemotherapy era: five years of experience. Ocul Oncol Pathol 2019;5:139–146.
6. Agrahari V, Mandal A, Agrahari V, Trinh HM, Joseph M, Ray A, et al. A comprehensive insight on ocular pharmacokinetics. Drug Deliv Transl Res 2016;6:735–754.
7. Willekens K, Reyns G, Diricx M, Vanhove M, Noppen B, Coudyzer W, et al. Intravitreally injected fluid dispersion: importance of injection technique. Invest Ophthalmol Vis Sci 2017;58:1434–1441.
8. Bonfiglio A, Repetto R, Siggers JH, Stocchino A. Investigation of the motion of a viscous fluid in the vitreous cavity induced by eye rotations and implications for drug delivery. Phys Med Biol 2013;58:1969–1982.
9. Modareszadeh A, Abouali O, Ghaffarieh A, Ahmadi G. Saccade movements effect on the intravitreal drug delivery in vitreous substitutes: a numerical study. Biomech Model Mechanobiol 2013;12:281–290.
10. Buitrago E, Winter U, Williams G, Asprea M, Chantada G, Schaiquevich P. Pharmacokinetics of melphalan after intravitreal injection in a rabbit model. J Ocul Pharmacol Ther 2016;32:230–235.
11. Ilochonwu BC, Urtti A, Hennink WE, Vermonden T. Intravitreal hydrogels for sustained release of therapeutic proteins. J Control Release 2020;326:419–441.
12. Mohammed MA, Syeda JTM, Wasan KM, Wasan EK. An overview of chitosan nanoparticles and its application in non-parenteral drug delivery. Pharmaceutics 2017;9: 53.
13. Zamboulis A, Nanaki S, Michailidou G, Koumentakou I, Lazaridou M, Ainali NM, et al. Chitosan and its derivatives for ocular delivery formulations: recent advances and developments. Polymers 2020;12:1519.
14. Liu D, Li J, Pan H, He F, Liu Z, Wu Q, et al. Potential advantages of a novel chitosan-N-acetylcysteine surface modified nanostructured lipid carrier on the performance of ophthalmic delivery of curcumin. Sci Rep 2016;6: 28796.
15. Bernkop-Schnürch A, Hornof M, Guggi D. Thiolated chitosans. Eur J Pharm Biopharm 2004;57:9–17.
16. Gilbert RE, Cox AJ, Kelly DJ, Wilkinson-Berka JL, Sage EH, Jerums G, et al. Localization of secreted protein acidic and rich in cysteine (SPARC) expression in the rat eye. Connect Tissue Res 1999;40:295–303.
17. Koo H, Moon H, Han H, Na JH, Huh MS, Park JH, et al. The movement of self-assembled amphiphilic polymeric nanoparticles in the vitreous and retina after intravitreal injection. Biomaterials 2012;33:3485–3493.
18. Delrish E, Jabbarvand M, Ghassemi F, Amoli FA, Atyabi F, Lashay A, et al. Efficacy of topotecan nanoparticles for intravitreal chemotherapy of retinoblastoma. Exp Eye Res 2021;204:108423.